Watch TMCI. Know when insiders buy.
One email the day a filing lands. Free.
TMCI
TREACE MEDICAL CONCEPTS, INC.
4.07
+0.19 +4.90%
USD · close Oct 20
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
61
WATCH · insiders 66, shorts 56
Insiders, 90 days
+$247K
net buying · 3 buys, 0 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $264.7MP/E —DIV YIELD —FCF YIELD -9.46%REV TTM $205.3M −4.0%NET INCOME −$59.5MNET DEBT $43.4M52W 1.20 – 6.87SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $45.4M | −4.2% | 78.5% | −$15M | −$15.9M | — | -0.24 | −$4.7M | $2.2M | −$6.9M | Aug 7 |
| Q1 2026 · Mar 31 | $47.2M | −10.2% | 79.3% | −$17.2M | −$18M | — | -0.28 | $7.2M | $3.1M | $4.2M | Aug 7 |
| Q4 2025 · Dec 31derived | $62.5M | −9.0% | 80.6% | −$5.9M | −$9.4M | — | -0.14 | −$8M | $2.4M | −$10.4M | Feb 27 |
| Q3 2025 · Sep 30 | $50.2M | +11.4% | 79.1% | −$15.7M | −$16.3M | — | -0.26 | −$9.1M | $2.8M | −$11.9M | Nov 6 |
| Q2 2025 · Jun 30 | $47.4M | +6.6% | 79.7% | −$17M | −$17.4M | — | -0.28 | −$3M | $4.8M | −$7.8M | Aug 7 |
| Q1 2025 · Mar 31 | $52.6M | +2.9% | 79.7% | −$15.6M | −$15.9M | — | -0.25 | $4.2M | $3.5M | $655K | Aug 7 |
| Q4 2024 · Dec 31derived | $68.7M | +10.4% | 80.7% | −$204K | −$501K | — | -0.01 | −$4.2M | $3.1M | −$7.3M | Feb 27 |
| Q3 2024 · Sep 30 | $45.1M | +10.6% | 80.1% | −$15.1M | −$15.4M | — | -0.25 | −$11.8M | $2.9M | −$14.7M | Nov 6 |
| Q2 2024 · Jun 30 | $44.5M | — | 80.2% | −$21.4M | −$21.2M | — | -0.34 | −$13.9M | $1.7M | −$15.6M | Nov 6 |
| Q1 2024 · Mar 31 | $51.1M | — | 80.2% | −$19M | −$18.7M | — | -0.30 | −$7.2M | $3.9M | −$11.1M | Nov 6 |
| Q4 2023 · Dec 31derived | $62.2M | — | 81.6% | −$6.8M | −$6.3M | — | -0.10 | $532K | $2.2M | −$1.7M | Feb 27 |
| Q3 2023 · Sep 30 | $40.8M | — | 80.4% | −$17.8M | −$17.5M | — | -0.28 | −$9.5M | $3.5M | −$13M | Nov 5 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $212.7M | 79.8% | −$54.2M | −$59M | -27.7% | -0.93 | −$16M | $13.5M | −$29.5M | — | — |
| FY2024 · to Dec 31 | $209.4M | 80.4% | −$55.7M | −$55.7M | -26.6% | -0.90 | −$37.2M | $11.6M | −$48.8M | — | — |
| FY2023 · to Dec 31 | $187.1M | 81.2% | −$51.4M | −$49.5M | -26.5% | -0.81 | −$34.6M | $11.5M | −$46M | — | — |
| FY2022 · to Dec 31 | $141.8M | 82.0% | −$34.8M | −$42.8M | -30.2% | -0.77 | −$30.6M | $14.8M | −$45.5M | — | — |
| FY2021 · to Dec 31 | $94.4M | 82.1% | −$16.5M | −$20.6M | -21.8% | -0.43 | −$17.2M | $2.7M | −$19.9M | — | — |
| FY2020 · to Dec 31 | $57.4M | 78.3% | $855K | −$3.7M | -6.4% | -0.12 | −$4.5M | $1.1M | −$5.6M | — | — |
Every number comes from TREACE MEDICAL CONCEPTS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.